1. Home
  2. LFS vs XBIT Comparison

LFS vs XBIT Comparison

Compare LFS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LFS

LEIFRAS Co. Ltd. American Depositary Shares

HOLD

Current Price

$2.39

Market Cap

92.9M

Sector

Real Estate

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.34

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFS
XBIT
Founded
2001
2005
Country
Japan
United States
Employees
1055
N/A
Industry
Other Consumer Services
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.9M
74.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LFS
XBIT
Price
$2.39
$2.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
300.9K
28.7K
Earning Date
04-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$2.09
52 Week High
$12.49
$3.61

Technical Indicators

Market Signals
Indicator
LFS
XBIT
Relative Strength Index (RSI) 58.73 44.68
Support Level $2.22 $2.35
Resistance Level $2.76 $2.41
Average True Range (ATR) 0.19 0.04
MACD 0.02 -0.00
Stochastic Oscillator 84.52 41.67

Price Performance

Historical Comparison
LFS
XBIT

About LFS LEIFRAS Co. Ltd. American Depositary Shares

Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: